The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
The Influence of Cell Cycle Regulation on Chemotherapy
Open accessAbstract
Cell cycle regulation is orchestrated by a complex network of interactions between proteins, enzymes, cytokines, and cell cycle signaling pathways, and is vital for cell proliferation, growth, and repair. The occurrence, development, and metastasis of tumors are closely related to the cell cycle. Cell cycle regulation can be synergistic with chemotherapy in two aspects: inhibition or promotion. The sensitivity of tumor cells to chemotherapeutic drugs can be improved with the cooperation of cell cycle regulation strategies. This review presented the mechanism of the commonly used chemotherapeutic drugs and the effect of the cell cycle on tumorigenesis and development, and the interaction between chemotherapy and cell cycle regulation in cancer treatment was briefly introduced. The current collaborative strategies of chemotherapy and cell cycle regulation are discussed in detail. Finally, we outline the challenges and perspectives about the improvement of combination strategies for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Xu, F., Na, L., Li, Y., & Chen, L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00416-0 · Cited by 539
RetractedIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“On the other hand, p53 activates the expression of Mdm2 gene in a self-regulating feedback loop [118].”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317 · cited 1×
“Activated p53 can participate in many important signaling pathways that control cell proliferation and death, including cell cycle regulation, DNA repair, metabolism, senescence, autophagy, and apoptosis [92,93].”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144 · cited 1×
“ROS can induce CHK1 activation or directly affect the protein phosphatase Cdc25 family (Cdc25A, B, and C) to promote cell cycle arrest [98].”
BackgroundRevisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Cell Cycle Checkpoints: Preventing an Identity Crisis
Elledge, S. J. (1996) · Science · doi:10.1126/science.274.5293.1664 · Cited by 2,039
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
DNA damage-induced cell death by apoptosis
Roos, W. P., & Kaina, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.007 · Cited by 1,500
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
Regulation of JAK–STAT signalling in the immune system
Shuai, K., & Liu, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1226 · Cited by 1,372
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Temozolomide resistance in glioblastoma multiforme
Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,163
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Murray, A. W. (2004) · Cell · doi:10.1016/s0092-8674(03)01080-8 · Cited by 1,053
Giordano, A., & Tommonaro, G. (2019) · Nutrients · doi:10.3390/nu11102376 · Cited by 1,000
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3185 · Cited by 947
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
The role of cellular reactive oxygen species in cancer chemotherapy
Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M., & Liang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0909-x · Cited by 794
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Cao, R., Peng, W., Wang, Z., & Xu, A. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707779940998 · Cited by 679
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
All tangled up: how cells direct, manage and exploit topoisomerase function
Vos, S. M., Tretter, E. M., Schmidt, B. H., & Berger, J. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3228 · Cited by 650
Ma, P., Xiao, H., Yu, C., Liu, J., Cheng, Z., Song, H., Zhang, X., Li, C., Wang, J., Gu, Z., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04269 · Cited by 649
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy
Xu, Z., Han, X., Ou, D., Liu, T., Li, Z., Jiang, G., Liu, J., & Zhang, J. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10257-8 · Cited by 612
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Cell Death from Antibiotics Without the Involvement of Reactive Oxygen Species
Liu, Y., & Imlay, J. A. (2013) · Science · doi:10.1126/science.1232751 · Cited by 593
Self-citationMutations in the NF-κB signaling pathway: implications for human disease
Courtois, G., & Gilmore, T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209939 · Cited by 525
Cellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R., Raghuwanshi, R., & Jain, P. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 511
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508
Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders
Wellington, K., & Jarvis, B. (2001) · BioDrugs · doi:10.2165/00063030-200115070-00005 · Cited by 479
Noh, J., Kwon, B., Han, E., Park, M., Yang, W., Cho, W., Yoo, W., Khang, G., & Lee, D. (2015) · Nature Communications · doi:10.1038/ncomms7907 · Cited by 461
Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels
Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074211 · Cited by 458
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
Rational design and latest advances of polysaccharide-based hydrogels for wound healing
Hu, H., & Xu, F.-J. (2020) · Biomaterials Science · doi:10.1039/d0bm00055h · Cited by 405
Self-citationCell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Riedl, S., Rinner, B., Asslaber, M., Schaider, H., Walzer, S., Novak, A., Lohner, K., & Zweytick, D. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.07.026 · Cited by 331
Tyagi, A. K., Singh, R. P., Agarwal, C., Chan, D. C. F., & Agarwal, R. (2002) · PubMed · Cited by 323
Battogtokh, G., Choi, Y. S., Kang, D. S., Park, S. J., Shim, M. S., Huh, K. M., Cho, Y.-Y., Lee, J. Y., Lee, H. S., & Kang, H. C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.006 · Cited by 310
Global control of cell-cycle transcription by coupled CDK and network oscillators
Orlando, D. A., Lin, C. Y., Bernard, A., Wang, J. Y., Socolar, J. E. S., Iversen, E. S., Hartemink, A. J., & Haase, S. B. (2008) · Nature · doi:10.1038/nature06955 · Cited by 307
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Hopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270
Activation of the ATR kinase by the RPA-binding protein ETAA1
Haahr, P., Hoffmann, S., Tollenaere, M. A. X., Ho, T., Toledo, L. I., Mann, M., Bekker-Jensen, S., Räschle, M., & Mailand, N. (2016) · Nature Cell Biology · doi:10.1038/ncb3422 · Cited by 256
The methotrexate story: A paradigm for development of cancer chemotherapeutic agents
Huennekens, F. M. (1994) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(94)90025-6 · Cited by 250
The emerging role of reactive oxygen species in cancer therapy
Renschler, M. F. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.031 · Cited by 237
Ocio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., Kumar, S., Usmani, S., Roodman, D., Niesvizky, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 233
DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
Raimondi, M. V., Randazzo, O., La Franca, M., Barone, G., Vignoni, E., Rossi, D., & Collina, S. (2019) · Molecules · doi:10.3390/molecules24061140 · Cited by 233
Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Shanmugam, M. K., Warrier, S., Kumar, A. P., Sethi, G., & Arfuso, F. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666170713094319 · Cited by 213
Cyclins and Cyclin–Dependent Kinases: Comparative Study of Hepatocellular Carcinoma Versus Cirrhosis
Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Yamagata, M., Kurokohchi, K., Uchida, N., Miyauchi, Y., Yoshiji, H., Watanabe, S., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50112 · Cited by 207
Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age
Ferreira, R., Schneekloth, J. S., Panov, K. I., Hannan, K. M., & Hannan, R. D. (2020) · Cells · doi:10.3390/cells9020266 · Cited by 183
B7-H3 in Cancer – Beyond Immune Regulation
Flem-Karlsen, K., Fodstad, Ø., Tan, M., & Nunes-Xavier, C. E. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.03.010 · Cited by 172
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury, A., Hall, S., Curtin, N., & Drew, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107450 · Cited by 171
DNA methylation and the preservation of cell identity
Bogdanović, O., & Lister, R. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.06.007 · Cited by 167
Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance
Makena, M. R., Ranjan, A., Thirumala, V., & Reddy, A. P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.015 · Cited by 166
Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent
Adjei, A. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040010 · Cited by 162
Toxic effects and involved molecular pathways of nanoparticles on cells and subcellular organelles
Liu, N., & Tang, M. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.3817 · Cited by 161
Mechanisms of replication fork protection: a safeguard for genome stability
Errico, A., & Costanzo, V. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.655374 · Cited by 159
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
Hong, D., Infante, J., Janku, F., Jones, S., Nguyen, L. M., Burris, H. A., Naing, A., Bauer, T. M., Piha-Paul, S., Johnson, F. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5788 · Cited by 159
Coussy, F., Botty, R. E., Château‐Joubert, S., Dahmani, A., Montaudon, É., Leboucher, S., Morisset, L., Painsec, P., Sourd, L., Huguet, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2625 · Cited by 159
Khan, H. Z., Reale, M., Ullah, H., Sureda, A., Tejada, S., Wang, Y., Zhang, Z., & Xiao, J. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.007 · Cited by 158
B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
Liu, H., Tekle, C., Chen, Y.-W., Kristian, A., Zhao, Y., Zhou, M., Liu, Z., Ding, Y., Wang, B., Mælandsmo, G. M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0072 · Cited by 157
Lallo, A., Frese, K. K., Morrow, C. J., Sloane, R. A. S., Gulati, S., Schenk, M. W., Trapani, F., Simms, N., Galvin, M., Brown, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2805 · Cited by 157
Wu, S., & Fu, L. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0775-3 · Cited by 146
Magnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K. R., Slipicevic, A., & Flørenes, V. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038254 · Cited by 144
Induction of oxidative stress by anticancer drugs in the presence and absence of cells
Yokoyama, C., Sueyoshi, Y., Ema, M., Mori, Y., Takaishi, K., & Hisatomi, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.6931 · Cited by 143
Dissenting degradation: Deubiquitinases in cell cycle and cancer
Bonacci, T., & Emanuele, M. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.008 · Cited by 135
ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells
Ronco, C., Martin, A. R., Demange, L., & Benhida, R. (2016) · MedChemComm · doi:10.1039/c6md00439c · Cited by 134
Singh, R. P., Gu, M., Sharma, G. D., Dhanalakshmi, S., Tyagi, A. K., Chan, D. C. F., Agarwal, C., & Agarwal, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1435 · Cited by 131
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Ye, W. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.03.015 · Cited by 129
Shimomura, T., Hasako, S., Nakatsuru, Y., Mita, T., Ichikawa, K., Kodera, T., Sakai, T., Nambu, T., Miyamoto, M., Takahashi, I., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0609 · Cited by 128
Glutamine Treatment Attenuates Endoplasmic Reticulum Stress and Apoptosis in TNBS-Induced Colitis
Crespo, I., San‐Miguel, B., Prause, C., Marroni, N. P., Cuevas, M. J., González‐Gallego, J., & Tuñón, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050407 · Cited by 124
Sen, T., Corte, C. M. D., Milutinovic, S., Cardnell, R. J., Diao, L., Ramkumar, K., Gay, C. M., Stewart, C. A., Fan, Y.-H., Shen, L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.009 · Cited by 123
Safe approaches for camptothecin delivery: Structural analogues and nanomedicines
Botella, P., & Rivero-Buceta, E. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.023 · Cited by 117
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
King, C., Diaz, H., Barnard, D., Barda, D. A., Clawson, D. K., Blosser, W. D., Cox, K. L., Guo, S., & Marshall, M. S. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0036-7 · Cited by 110
Chand, S., Mahajan, R. V., Prasad, J. P., Sahoo, D. K., Mihooliya, K. N., Dhar, M. S., & Sharma, G. D. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1888 · Cited by 106
Marine Polysaccharides as a Versatile Biomass for the Construction of Nano Drug Delivery Systems
Sun, Y., Ma, X., & Hu, H. (2021) · Marine Drugs · doi:10.3390/md19060345 · Cited by 103
Self-citationCombined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Jin, J., Fang, H., Yang, F., Ji, W., Guan, N., Sun, Z., Shi, Y., Zhou, G., & Guan, X. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.003 · Cited by 101
Yu, Q., Zeng, K., Ma, X., Song, F., Jiang, Y., Tu, P., & Wang, X. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.010 · Cited by 100
Self-citationTang, J., Yang, L., Chen, J., Li, Q., Zhu, L., Xu, Q., Huang, G., Zhang, Z., Xiang, Y., Du, L., et al. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0424-2 · Cited by 100
Khoury, A., Deo, K. M., & Aldrich-Wright, J. R. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111070 · Cited by 100
Tentori, L., Ricci‐Vitiani, L., Muzi, A., Ciccarone, F., Pelacchi, F., Calabrese, R., Runci, D., Pallini, R., Caiafa, P., & Graziani, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-151 · Cited by 98
Liu, Z., Zhang, W., Phillips, J. B., Arora, R., McClellan, S. B., Li, J., Kim, J. H., Sobol, R. W., & Tan, M. (2018) · Oncogene · doi:10.1038/s41388-018-0407-9 · Cited by 96
Murrow, L. M., Garimella, S. V., Jones, T. L., Caplen, N. J., & Lipkowitz, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0571-2 · Cited by 92
Liu, L., Xiong, D., Lin, P., Yang, H., Dang, Y., & Chen, G. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4531 · Cited by 90
Unleashing Chk1 in cancer therapy
Carrassa, L., & Damia, G. L. M. (2011) · Cell Cycle · doi:10.4161/cc.10.13.16398 · Cited by 88
Lowery, C. D., Dowless, M. S., Renschler, M., Blosser, W. D., VanWye, A. B., Stephens, J. R., Iversen, P. W., Bence, A. K., Beckmann, R. P., Krytska, K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2728 · Cited by 86
Italiano, A., Infante, J. R., Shapiro, G. I., Moore, K. N., LoRusso, P. M., Hamilton, E. P., Cousin, S., Toulmonde, M., Postel-Vinay, S. C., Tolaney, S. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy076 · Cited by 81
Davies, A. M., Chansky, K., Lara, P. N., Gumerlock, P. H., Crowley, J. J., Albain, K. S., Vogel, S. J., & Gandara, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181915052 · Cited by 80
Rozengurt, E. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199903000-00007 · Cited by 79
Combès, E., Andrade, A. F., Tosi, D., Michaud, H., Coquel, F., Garambois, V., Désigaud, D., Jarlier, M., Coquelle, A., Pasero, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2807 · Cited by 78
Transcriptional control of stem cell fate by E2Fs and pocket proteins
Julian, L. M., & Blais, A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00161 · Cited by 76
Karlsen, K. F., Tekle, C., Andersson, Y., Flatmark, K., Fodstad, Ø., & Nunes‐Xavier, C. E. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12599 · Cited by 75
Anthracyclines and Mitochondria
Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_18 · Cited by 74
Cole, K. A., Pal, S., Kudgus, R. A., Ijaz, H., Liu, X., Minard, C. G., Pawel, B., Maris, J. M., Haas-Kogan, D. A., Voss, S. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3470 · Cited by 74
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Angius, G., Tomao, S., Stati, V., Vici, P., Bianco, V., & Tomao, F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03950-y · Cited by 73
Gomes, L. R., Rocha, C. R. R., Martins, D. J., Fiore, A. P. Z. P., Kinker, G. S., Bruni‐Cardoso, A., & Menck, C. F. M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1689-8 · Cited by 71
Tumour selective targeting of cell cycle kinases for cancer treatment
Aarts, M., Linardopoulos, S., & Turner, N. C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.012 · Cited by 69
Beck, R., Pedrosa, R. C., Dejeans, N., Glorieux, C., Levêque, P., Gallez, B., Taper, H. S., Eeckhoudt, S., Knoops, L., Calderón, P. B., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9441-3 · Cited by 67
Nam, H.-J., Im, S., Oh, D., Elvin, P., Kim, H., Yoon, Y., Min, A., Song, S., Han, S., Kim, T., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0109 · Cited by 66
Zhang, X., Qin, X., Wei, R., Song, H., Mi, J., Lin, Z., Yang, Y., Sun, Z., & Zou, K. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.04.009 · Cited by 66
Wei, F., Yan, J. J., & Tang, D. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798194388 · Cited by 65
He, C.-S., Liu, Y.-C., Xu, Z., Dai, P.-C., Chen, X., & Jin, D.-H. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453175 · Cited by 65
Self-citationLogical design and application of prodrug platforms
Meng, Q., Hu, H., Zhou, L., Zhang, Y., Yu, B., Shen, Y., & Cong, H. (2018) · Polymer Chemistry · doi:10.1039/c8py01160e · Cited by 65
Self-citationChapter 9 Regulation of Human Dihydrofolate Reductase Activity and Expression
Abali, E. E., Skacel, N. E., Çelikkaya, H., & Hsieh, Y. (2008) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00409-3 · Cited by 63
Dynamics of Uracil and 5-Fluorouracil in DNA
Parker, J. B., & Stivers, J. T. (2010) · Biochemistry · doi:10.1021/bi101536k · Cited by 63
Hsu, W., Zhao, X., Zhu, J., Kim, I., Rao, G., McCutcheon, J. N., Hsu, S.-T., Teicher, B. A., Kallakury, B., Dowlati, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.028 · Cited by 63
Anticancer polymers designed for killing dormant prostate cancer cells
Takahashi, H., Yumoto, K., Yasuhara, K., Nadres, E. T., Kikuchi, Y., Buttitta, L., Taichman, R. S., & Kuroda, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-36608-5 · Cited by 63
Chen, X., Xie, F., Zhu, X.-J., Lin, F., Pan, S.-S., Gong, L.-H., Qiu, J.-G., Zhang, W., Jiang, Q., Mei, X.-L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3717 · Cited by 62
Jing, X., Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · Biomaterials Science · doi:10.1039/d1bm00911g · Cited by 62
Self-citationSilencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma
ZHAO, X., Zhang, G., Gan, W.-J., XIONG, F., Li, Z., Zhao, H., Zhu, D., Zhang, B., Zhang, X., & Li, D. (2013) · Oncology Letters · doi:10.3892/ol.2013.1118 · Cited by 61
Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells
Elliott, B., Millena, A. C., Matyunina, L. V., Zhang, M., Zou, J., Wang, G., Zhang, Q., Bowen, N. J., Eaton, V., Webb, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.005 · Cited by 59
Riesterer, O., Matsumoto, F., Wang, L., Pickett, J., Molkentine, D. P., Giri, U. P., Milas, L., & Raju, U. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9361-2 · Cited by 56
Wu, Y., Ma, J., Sun, Y., Tang, M. X., & Kong, L. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.126913 · Cited by 56
Self-citationLang, L., Shay, C., Xiong, Y., Thakkar, P., Chemmalakuzhy, R., Wang, X., & Teng, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0623-3 · Cited by 55
Sizek, H., Hamel, A. R., Deritei, D., Campbell, S., & Regan, E. R. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006402 · Cited by 54
Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations
Atwal, M., Swan, R. L., Rowe, C., Lee, K. C., Lee, D. C., Armstrong, L., Cowell, I. G., & Austin, C. A. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.117259 · Cited by 54
Revision of the concept of anti‐angiogenesis and its applications in tumor treatment
Yang, W., Xu, J., Mu, J., & Xie, J. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.01.002 · Cited by 53
B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells
Zhang, W., Wang, J., Wang, Y., Dong, F., Zhu, M., Wan, W., Li, H.-S., Wu, F., Yan, X., & Ke, X. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s85272 · Cited by 52
Application of Nano-Drug Delivery System Based on Cascade Technology in Cancer Treatment
Sun, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115698 · Cited by 52
Self-citationGao, P., Wang, L., Liu, J., Dong, F., Song, W., Liao, L., Wang, B., Zhang, W., Zhou, X., Xie, Q., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117221 · Cited by 49
Zhao, Y., Foster, N. R., Meyers, J. P., Thomas, S. P., Northfelt, D., Rowland, K. M., Mattar, B. I., Johnson, D. B., Molina, J. R., Mandrekar, S. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000383 · Cited by 47
Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells
Zhang, P., Chen, Z., Ning, K., Jin, J., & Han, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.001 · Cited by 43
Sun, Y., Hu, H., Jing, X., Meng, Q., Yu, B., Cong, H., & Shen, Y. (2021) · Science China Materials · doi:10.1007/s40843-020-1627-4 · Cited by 43
Self-citationPolymer nanoparticle-assisted chemotherapy of pancreatic cancer
Su, T., Yang, B., Gao, T., Liu, T., & Li, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920915978 · Cited by 42
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells
Duan, L., Perez, R. E., Chastain, P. D., Mathew, M. T., Bijukumar, D. R., & Maki, C. G. (2019) · Oncogene · doi:10.1038/s41388-019-0814-6 · Cited by 41
Lama-Sherpa, T. D., & Shevde, L. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0665 · Cited by 41
Ma, Y., Wang, R., Lu, H., Li, X., Zhang, G., Fu, F., Cao, L., Zhan, S., Wang, Z., Deng, Z., et al. (2020) · Journal of Cancer · doi:10.7150/jca.37255 · Cited by 40
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
Chen, Y., & Du, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.094 · Cited by 39
Structure-based studies on species-specific inhibition of thymidylate synthase
Costi, M. P., Tondi, D., Rinaldi, M., Barlocco, D., Pecorari, P., Soragni, F., Venturelli, A., & Stroud, R. M. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00083-2 · Cited by 37
Signaling pathway switch in breast cancer
Guillé, A., Chaffanet, M., & Birnbaum, D. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-66 · Cited by 34
Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma
Geng, M., Yang, Y., Cao, X., Dang, L., Zhang, T., & Zhang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.052 · Cited by 34
Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis
Rodríguez, E., Quereda, V., Bellutti, F., Prchal‐Murphy, M., Partida, D., Eguren, M., Kollmann, K., de Cedrón, M. G., Dubus, P. R., Cañamero, M., et al. (2014) · Blood · doi:10.1182/blood-2014-02-555292 · Cited by 33
Implication of sphingolipid metabolism in the stability of the Golgi apparatus
Fukunaga, T., Nagahama, M., Hatsuzawa, K., Tani, K., Yamamoto, A., & Tagaya, M. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.18.3299 · Cited by 32
Huang, L., Shan, Y., He, C., Ren, M., Tian, P., & Song, W. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2015.12.024 · Cited by 31
Warren, N. J. H., & Eastman, A. R. (2019) · Oncogene · doi:10.1038/s41388-019-1079-9 · Cited by 29
Grellety, T., Callens, C., Richard, É., Briaux, A., Velasco, V., Pulido, M., Gonçalvès, A., Gestraud, P., MacGrogan, G. M., Bonnefoi, H. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1469 · Cited by 28
Morrow, C. J., Ghattas, M. A., Smith, C. G., Bönisch, H., Bryce, R. A., Hickinson, D. M., Green, T. P., & Dive, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0694 · Cited by 26
Yusenko, M. V., Jakobs, A., & Klempnauer, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-31620-1 · Cited by 26
Hahm, E., Lee, J., Abella, T., & Singh, S. V. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23104 · Cited by 24
Sun, Y., Ma, X., Jing, X., & Hu, H. (2021) · Nanomaterials · doi:10.3390/nano11071640 · Cited by 23
Self-citationIjichi, K., Adachi, M., Ogawa, T., Hasegawa, Y., & Murakami, S. (2014) · PubMed · Cited by 21
Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity
Zhang, L., Guo, J., Jiang, X.-M., Chen, X.-P., Wang, Y.-T., Li, A., Lin, L., Li, H., & Lu, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0332-7 · Cited by 20
Kuo, C.-H., Leu, Y., Wang, T., Tseng, W.-C., Feng, C.-H., Wang, S., & Chen, C. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102690 · Cited by 19
Marcus, J. M., Burke, R. T., Doak, A. E., Park, S., & Orth, J. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1480224 · Cited by 18
Patel, P. R., Senyuk, V. I., Rodriguez, N. S., Oh, A. L., Bonetti, E., Mahmud, D. L., Barosi, G., Mahmud, N., & Rondelli, D. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.841 · Cited by 16
Hsieh, M., Hsieh, M., Lo, Y., Lin, C., Chuang, Y., Chen, M., & Chou, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110318 · Cited by 14
Conzemius, M. G., Graham, J. C., Haynes, J. S., & Graham, C. A. (2000) · American Journal of Veterinary Research · doi:10.2460/ajvr.2000.61.646 · Cited by 13
Targeting the centrosome and polo-like kinase 4 in osteosarcoma
Kelleher, F. C., Kroes, J., & Lewin, J. H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy175 · Cited by 13
Aubets, E., Noé, V., & Ciudad, C. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113911 · Cited by 13
Cheng, M. S.-Q., Su, M. X.-X., Wang, M. X.-N., Sun, M. Z.-Y., & Ou, T. (2019) · Methods · doi:10.1016/j.ymeth.2019.06.004 · Cited by 6
Cited by
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Metadata
- Authors
- Sun, Y., Liu, Y., Ma, X., & Hu, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-28
- Volume
- 22
- Issue
- 13
- Pages
- 6923
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3176540806
- Cited by
- 290
- References
- 170
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.